RU2014153675A - Антитела к с-концевым и центральным эпитопам а-бета - Google Patents
Антитела к с-концевым и центральным эпитопам а-бета Download PDFInfo
- Publication number
- RU2014153675A RU2014153675A RU2014153675A RU2014153675A RU2014153675A RU 2014153675 A RU2014153675 A RU 2014153675A RU 2014153675 A RU2014153675 A RU 2014153675A RU 2014153675 A RU2014153675 A RU 2014153675A RU 2014153675 A RU2014153675 A RU 2014153675A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- cdr
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 125
- 238000000034 method Methods 0.000 claims abstract 121
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract 15
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 14
- 150000001413 amino acids Chemical class 0.000 claims abstract 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 20
- 210000004899 c-terminal region Anatomy 0.000 claims 9
- 238000002600 positron emission tomography Methods 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- MYNQXTDIPMCJCR-HUYCHCPVSA-N 2-[2-fluoranyl-6-(methylamino)pyridin-3-yl]-1-benzofuran-5-ol Chemical compound [18F]C1=NC(NC)=CC=C1C1=CC2=CC(O)=CC=C2O1 MYNQXTDIPMCJCR-HUYCHCPVSA-N 0.000 claims 1
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261667891P | 2012-07-03 | 2012-07-03 | |
| US61/667,891 | 2012-07-03 | ||
| PCT/US2013/046399 WO2014007982A2 (en) | 2012-07-03 | 2013-06-18 | C-terminal and central epitope a-beta antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014153675A true RU2014153675A (ru) | 2016-08-27 |
Family
ID=49882576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014153675A RU2014153675A (ru) | 2012-07-03 | 2013-06-18 | Антитела к с-концевым и центральным эпитопам а-бета |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150353631A1 (enExample) |
| EP (1) | EP2869846A4 (enExample) |
| JP (1) | JP2015526409A (enExample) |
| KR (1) | KR20150036163A (enExample) |
| CN (1) | CN105579061A (enExample) |
| AU (1) | AU2013287119A1 (enExample) |
| BR (1) | BR112014033066A2 (enExample) |
| CA (1) | CA2877516A1 (enExample) |
| HK (1) | HK1208810A1 (enExample) |
| IL (1) | IL236549A0 (enExample) |
| MX (1) | MX2014015744A (enExample) |
| RU (1) | RU2014153675A (enExample) |
| WO (1) | WO2014007982A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078121A1 (en) * | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| BR112017001385B1 (pt) | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| ES2987034T3 (es) | 2014-08-05 | 2024-11-13 | Apollomics Inc | Anticuerpos anti-PD-L1 |
| US20180344881A1 (en) * | 2015-11-20 | 2018-12-06 | Navidea Biopharmaceuticals, Inc. | Formulations for 2-heteroaryl substituted benzofurans |
| KR102799807B1 (ko) * | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| CN105542005B (zh) * | 2016-02-03 | 2018-11-09 | 大连理工大学 | 一种抗人淀粉样β肽的纳米抗体及其应用 |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| ES2971881T3 (es) | 2016-08-19 | 2024-06-10 | Beigene Switzerland Gmbh | Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
| CN118382636A (zh) | 2021-12-17 | 2024-07-23 | 豪夫迈·罗氏有限公司 | 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9125798A (en) * | 1997-08-28 | 1999-03-16 | University Of Washington | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| SK288723B6 (sk) * | 2000-02-24 | 2020-01-07 | Univ Washington | Farmaceutický prostriedok a použitie tohto farmaceutického prostriedku |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| WO2005018424A2 (en) * | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| AR051800A1 (es) * | 2004-12-15 | 2007-02-07 | Wyeth Corp | Anticuerpos a beta usados en mejorar la cognicion |
| US20060210557A1 (en) * | 2005-01-28 | 2006-09-21 | Donna Luisi | Stabilized liquid polypeptide formulations |
| MY167887A (en) * | 2005-12-12 | 2018-09-26 | Ac Immune Sa | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| US20100239570A1 (en) * | 2007-09-13 | 2010-09-23 | Roger Nitsch | Moncolonal amyloid beta (abeta) - specific antibody and uses thereof |
| WO2011133919A1 (en) * | 2010-04-22 | 2011-10-27 | Janssen Alzheimer Immunotherapy | Use of tau to monitor immunotherapy |
| WO2011106732A1 (en) * | 2010-02-25 | 2011-09-01 | Wyeth Llc | Pet monitoring of ab-directed immunotherapy |
-
2013
- 2013-06-18 JP JP2015520289A patent/JP2015526409A/ja not_active Abandoned
- 2013-06-18 BR BR112014033066A patent/BR112014033066A2/pt active Search and Examination
- 2013-06-18 RU RU2014153675A patent/RU2014153675A/ru not_active Application Discontinuation
- 2013-06-18 HK HK15109545.4A patent/HK1208810A1/xx unknown
- 2013-06-18 CN CN201380035339.9A patent/CN105579061A/zh active Pending
- 2013-06-18 US US14/410,018 patent/US20150353631A1/en not_active Abandoned
- 2013-06-18 CA CA2877516A patent/CA2877516A1/en not_active Abandoned
- 2013-06-18 WO PCT/US2013/046399 patent/WO2014007982A2/en not_active Ceased
- 2013-06-18 AU AU2013287119A patent/AU2013287119A1/en not_active Abandoned
- 2013-06-18 KR KR20157001775A patent/KR20150036163A/ko not_active Withdrawn
- 2013-06-18 MX MX2014015744A patent/MX2014015744A/es unknown
- 2013-06-18 EP EP13812620.6A patent/EP2869846A4/en not_active Withdrawn
-
2015
- 2015-01-01 IL IL236549A patent/IL236549A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014015744A (es) | 2015-06-05 |
| BR112014033066A2 (pt) | 2017-08-01 |
| HK1208810A1 (en) | 2016-03-18 |
| EP2869846A2 (en) | 2015-05-13 |
| KR20150036163A (ko) | 2015-04-07 |
| AU2013287119A1 (en) | 2015-01-22 |
| WO2014007982A2 (en) | 2014-01-09 |
| US20150353631A1 (en) | 2015-12-10 |
| WO2014007982A3 (en) | 2014-04-03 |
| CN105579061A (zh) | 2016-05-11 |
| CA2877516A1 (en) | 2014-01-03 |
| IL236549A0 (en) | 2015-02-26 |
| EP2869846A4 (en) | 2016-01-13 |
| JP2015526409A (ja) | 2015-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014153675A (ru) | Антитела к с-концевым и центральным эпитопам а-бета | |
| CN115417916B (zh) | 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断 | |
| KR102533675B1 (ko) | 타우 인식 항체 | |
| WO2015032906A4 (en) | Cd70-binding peptides and method, process and use relating thereto | |
| JP2015526409A5 (enExample) | ||
| JP2014533357A5 (enExample) | ||
| JP2016104026A5 (enExample) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| JP2014511179A5 (enExample) | ||
| CN109219615A (zh) | 识别tau的抗体 | |
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| RU2012140954A (ru) | Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других а-синуклеинопатий | |
| JP2014524733A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2012139043A (ru) | Эпитоп, специфичный к олигомеру амилоида бета, и антитела | |
| AU2024216442A1 (en) | Methods for treating Alzheimer's disease | |
| EP2928494A1 (en) | A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES | |
| RU2014108309A (ru) | Антиполиубиквитиновые антитела и способы применения | |
| KR20250054840A (ko) | Sars-cov-2를 표적으로 하는 항원 결합 분자 | |
| RU2019122337A (ru) | Раннее обнаружение активации глиальных клеток при нейродегенеративных или нейровоспалительных заболеваниях | |
| IL315266A (en) | Anti-coagulation factor xi antibodies | |
| RU2016135962A (ru) | Выделенное антитело, способ его получения, выделенная нуклеиновая кислота, экспрессионная кассета, клетка-хозяин, фармацевтический и диагностический препараты, способ лечения больного, подверженного риску или страдающего от инфекции E.COLI, и способ диагностики определения инфекций E.COLI | |
| JP2017526618A5 (enExample) | ||
| JP7210612B2 (ja) | 抗ａベータ抗体及びその使用 | |
| JP2012523221A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180315 |